The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial

Jiann Shing Jeng, Yu Sun, Jiunn Tay Lee, Ruey Tay Lin, Chih Hung Chen, Helen L. Po, Huey Juan Lin, Chung Hsiang Liu, Ming Hui Sun, Mu Chien Sun, Chang Ming Chern, Li Ming Lien, Hou Chang Chiu, Han Hwa Hu, Hung Yi Chiou, Sien Tsong Chen, Henry Ma, Chung Y. Hsu, SPAD Study Investigators

研究成果: 雜誌貢獻文章

9 引文 斯高帕斯(Scopus)

摘要

Rationale: It is not uncommon for patients with ischemic stroke to have peripheral arterial disease (PAD). Patients with polyvascular diseases carry greater burden of atherosclerosis and higher risks of developing vascular events and death. More effective regimens, such as dual antiplatelet agents, may be more effective for controlling progression of atherosclerosis in secondary prevention. Aim: This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease. Design: The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients with Peripheral Arterial Disease (SPAD) study is a randomized double-blinded placebo-controlled trial. Patients with previous ischemic stroke or TIA who had been taking aspirin (100mg per day), aged 50 years or older, with PAD in the lower limbs based on ankle-brachial index (ABI)
原文英語
頁(從 - 到)123-127
頁數5
期刊International Journal of Stroke
10
發行號1
DOIs
出版狀態已發佈 - 一月 1 2015

    指紋

ASJC Scopus subject areas

  • Neurology
  • Medicine(all)

引用此

Jeng, J. S., Sun, Y., Lee, J. T., Lin, R. T., Chen, C. H., Po, H. L., Lin, H. J., Liu, C. H., Sun, M. H., Sun, M. C., Chern, C. M., Lien, L. M., Chiu, H. C., Hu, H. H., Chiou, H. Y., Chen, S. T., Ma, H., Hsu, C. Y., & SPAD Study Investigators (2015). The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial. International Journal of Stroke, 10(1), 123-127. https://doi.org/10.1111/ijs.12384